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ABSTRACT
Biomedical endeavours can be divided into three major categories: research, education, and testing.
Within the context of each of these categories, activities involving whole animals have made major
contributions and will continue to do so in the future. However, with technological developments in the
areas of biotechnology and computers, new methods are already reducing the use of whole animals in
certain areas. This article discusses the general tissues of alternatives and then focuses on the
development of new approaches to toxicity testing.

Introduction
In recent years, societal concerns over the use of animals in various biomedical activities have
significantly increased. The ethical issues involved are not new; however, increased awareness of these
issues in the scientific community has led to an increased emphasis on the development of new
approaches to conducting these traditional activities (1). In the simplest analysis, biomedical activities can
be classified into three categories: research, education, and testing. Biomedical research involves the
discovery of new knowledge relating to the nature of disease processes and their treatment. These
activities have traditionally used animals as models to develop an understanding of the human condition.
Despite limitations when using animal models, few question that this approach has been highly
successful. Education involves the process of information transfer and can be subdivided into the transfer
of factual knowledge and the transfer of skills. Again, animals have been used in activities ranging from
teaching students basic principles of physiology to training future surgeons in sophisticated surgical
procedures. Testing is a focused activity designed to evaluate the hazards (commercial chemicals) or
safety (pharmaceuticals) involved in the use of new chemicals or formulations for beneficial purposes.
Over the past 60 years, testing strategies based on whole animal procedures have evolved to provide the
experimental database for safety/hazard evaluation. In all three categories, historical precedents have
been established that focus on animal models as the foundation for biomedical progress. The important

question today is whether alternatives exist that can satisfactorily substitute for the currently employed
whole animal models in the various biomedical activities.
The likelihood of implementing alternatives in each of the areas of biomedical application -- research,
education, and testing -- differs from one area to the next. With respect to refinement and reduction
alternatives either are under evaluation or, in many cases, have already been implemented in all areas of
biomedical activities. However, when one discusses the possibility of alternatives as full replacements for
ongoing approaches, it is necessary to consider each application separately. Replacement alternatives
have already been implemented in many areas of education, based on computer and simulation
technologies. However, in the area of skilled training (surgical training), it is difficult to envisage the
possibility of total replacement. Much can be .done to decrease the use of animals, and endeavours to
reach this goal should be encouraged.
For bio-medical research, the concept of replacement is also difficult for most to perceive. Research
science is driven by the questions that arise out of clinical experience, laboratory investigation, or human
accidents. The purpose of research--is the discovery of new knowledge; and understanding specific
biological systems most likely necessitates the use of ·whole-animal models. Many biomedical research
approaches are currently based on in vitro systems that, in each particular case, represent the best
scientific approach. The interaction between whole animals and in vitro models in research is not an
either/or situation, but a matter of degree.
In the area of testing, which has received considerable attention in recent years, much progress has
already been made in the implementation and development of alternatives. Whether it is possible to fully
replace whole animal use is unclear, although animal use can be greatly reduced. The remainder of this
article will explore in more detail the issue of testing.
Toxicity Testing
Industrial technology of the 20th century is capable of producing new chemicals at a rate of several
thousand new chemicals and formulations each year. It is essential that any detrimental side-effects that
may be associated with the introduction of these new chemicals be identified and evaluated in a timely
and efficient manner. In addition, adverse effects resulting from exposure in the occupational environment
or accidental exposure of non-target organisms must be elucidated and appropriate remedial procedures
established.
Hazard identification, exposure estimation, and the exposure-response relationship are the three major
activities of risk assessment. Hazard identification is the process by which potential toxicological problems
resulting from the manufacture and use of chemicals are elucidated. Exposure estimation gives some
indication of how many people will be exposed to what concentrations, for how long, and under what
conditions (route of exposure). For a chemical agent to be of toxicological concern, a reasonable
likelihood of human exposure to the agent, in quantities sufficient to produce adverse biological effects
must exist. The third activity associated with the risk assessment process, the development of exposureresponse relationships, provides a quantitative relationship of the chance for developing a particular
adverse response as a function of exposure to the chemical. Presumably, one such relationship exists for
each possible adverse outcome (cancer, kidney damage, reproductive effects, etc.). Exposure-response
relationships depend on many factors that affect the intrinsic toxicity of a chemical, such as route of
exposure (ingestion, inhalation, dermal contact) and host characteristics (age, nutritional status, genetic
background, among others). Combining exposure and the exposure-response relationship provides a
quantitative estimate of the potential toxicological risk of a given chemical to a given population under the
conditions of proposed use.

Within the context of risk assessment, the main objectives of toxicity testing are: a) to determine which
potential adverse effects are of concern for a given chemical (hazard identification); and b) to provide
adequate data to estimate the quantitative exposure-response relationship in the animal of concern.
Traditionally, these goals were attained through the use of whole-animal studies. Early toxicity testing in
the 1920s and 1930s focused mainly on evaluating acute lethality. The LD50 test was developed to
provide a statistically-defined estimate of the dose of a chemical that produced 50% mortality in a
population of animals. Later, in the 1940s, ocular irritation testing was standardised by the Draize protocol
(2). Over the years, other procedures were developed to evaluate various aspects of toxicological
concern.
In vitro systems have been traditionally employed in biomedical research. In the 18th and 19th centuries,
classic in vitro experiments on muscle physiology were conducted with isolated muscle preparations.
Since then, many other in vitro systems have been developed to investigate physiological and
biochemical processes (3). Only recently have in vitro systems been utilised in the area of toxicity testing
(4). Carcinogen testing initially was the major focus of in vitro toxicity testing, the result of pioneering work
by Ames. et al. (5, 6) on Salmonella-based mutagenicity test systems in the late 1960s and 1970s. More
recently, the use of in vitro systems has been advocated for evaluating toxicological responses in areas
other than carcinogenic risk. In the mid-1970s, interest in in vitro alternatives to in vivo teratogenicity
testing developed. Later, the areas of acute toxicity, particularly the LD50 (7, 8), and ocular irritation,
received major attention. However, in a review of ocular irritation testing by the US Environmental
Protection Agency in 1981, only five in vitro test systems were identified (9).
Since 1980, rapid developments have occurred in the field of in vitro toxicity testing. Initially, these efforts
were promoted by individuals (3, 7, 8, 10). However, early on, several organisations developed to pursue
these activities. In the United States, the first major programme to focus on alternatives to Draize ocular
irritation testing was initiated at Rockefeller University under the direction of Dr Dennis Stark, and
supported by the Revlon Corporation. Soon afterwards, the Cosmetic, Toiletry and Fragrance Association
provided support to establish the Johns Hopkins Center for Alternatives to Animal Testing (CAAT), under
the direction of Dr Alan Goldberg. Both of these organisations have fostered the development of in vitro
toxicity testing in the United States. In Europe, the major organisations involved in alternative testing
issues are the Fund for the Replacement of Animals in Medical Experiments (FRAME), coordinated by Dr
Michael Balls of the University of Nottingham, UK, and the European Research Group for Alternatives in
Toxicity Testing (ERGATT). Together, these four organisations have had a major impact on in vitro
toxicity testing outside the realm of carcinogenicity testing. Recently, the Japanese Society for
Alternatives to Animal Experiments was established.
Technological developments in the areas of cell culture and bioanalytical techniques have opened new
avenues for in vitro toxicity testing. New approaches to culturing important cell types led to the
development of new test systems. Developments in bioanalytical techniques, such as monoclonal
antibodies that allow for the analysis of marker proteins as test endpoints, also contribute to the
development of new tests. Combining new cell cultures with new ways to measure toxicologicla endpoints
stimulates advances in in vitro toxicity testing technology.
Classification of Testing Objectives
Before discussing specific testing activities, it is useful to have some perspective on the general
objectives of these activities. Toxicity testing can be performed at various levels with respect to the
toxicological information derived (Figure 1). Listed in increasing order of information content, terms used
to describe these levels are toxic potential, potency, hazard assessment, and risk assessment.

Assessment of toxic potential determines the mere possibility that a chemical can produce an adverse
effect independent of its likelihood or its severity under expected conditions of exposure. Potency
evaluations provide the next highest level of information; determination of potency establishes the relative
toxicity of a chemical and can be used to rank or classify chemicals. Potency measurements, although
often quantitative in nature, depend on the test system used for the assessment and therefore do not
provide absolute measures of toxicity. Hazard assessment, on the other hand, is quantitative and
provides specific information on the likelihood of particular adverse effects in the animal of interest.
Finally, risk assessment, the highest level of information, specifies the probability of an adverse effect
occurring within a population given a particular likelihood of exposure. Particular toxicity testing activities
can be focused at any one of these levels of toxicity evaluation.
Figure 1: Classification of in vitro toxicity testing by level of testing and type of testing
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Level of testing is listed in increasing order of information content. Shaded boxes indicate areas where in vitro testing
is currently being applied, and open boxes show areas in which in vitro testing is under development. (See text for
definition of terms).

From a different perspective, the objective of a testing activity can be categorised by the type of testing:
screening, as adjuncts, or as replacements. Screening tests are preliminary activities expected to be
followed by more definitive testing. Screening can be used to set priorities; for example, which chemicals
should be retained in development programme based on the likelihood of lower toxicity. The screening
test does not make a final determination on toxicity, but is used as a component of the decision-making

process in product development. A second type of testing is as adjuncts. Here the testing information is
more definitive than it is in screening, but it is not sufficient in and of itself for making final regulatory
decisions. Several categories of testing activities fall into this area. One is mechanistic studies in in vitro
systems that help resolve discrepancies in animal test data; another is tests used as early tiers in a tier
testing strategy for toxicity classification. Another area where in vitro tests can serve as adjuncts is for
evaluation of the intrinsic cellular toxicity of chemicals. By using a battery of in vitro systems to develop
basic information about the mechanism of action of a chemical, important toxicological information can be
developed to aid in the final safety evaluation. Finally, in vitro tests have been proposed as replacements
for existing in vivo testing procedures. The replacement of classic whole-animal testing activities is not yet
possible and will require significant scientific developments, particularly in the area of in vitro/in vivo
extrapolation, before it becomes a reality.
In Vitro Tests
In vitro tests are rapidly being developed as alternatives to using whole animals in various areas of
toxicity testing. Research activities can be classified into at least seven categories: cytotoxicity;
inflammation and irritation; genotoxicity; teratogenicity; target organ toxicity; toxicokinetics; and structureactivity relationships. Although not necessarily an inclusive listing, these categories cover the most
general areas in which in vitro approaches are actively being investigated.
Cytotoxicity
In vitro cytotoxicity assays have a long history, arid many have been developed over the years (4, 11).
Some were developed for special purposes, such as screening potential antineoplastic drugs for their
ability to kill cancer cells, while others were developed for more general purposes. Cytotoxicity can be
evaluated with any cell type that can be cultured in vitro, and the number of methods for evaluating
whether cells are viable has increased in recent years. Thus, a multiplicity of test systems are available.
Two cytotoxicity test systems that have received particular' attention are the assay developed by FRAME
(12), and the neutral red uptake assay developed by the research group at Rockefeller University (13).
Inflammation and irritation
Research in this area involves eye and skin irritation problems. Most toxicologists are familiar with the
Draize eye test, but alternative approaches to ocular irritation testing are clearly needed. Significant
research effort has focused on developing in vitro methods to provide information equivalent to that
obtained from either the Draize eye or skin test. The Johns Hopkins CAAT identified 34 potential in vitro
tests that can contribute to ocular irritation testing (14).
Genotoxicity
Many approaches to mutagenicity and carcinogenicity testing, beginning with the Ames assay, have been
proposed or are under development (15). Genotoxicity has probably been the most adequately funded
and active area of in vitro approaches to toxicity testing, because conducting whole-animal tests for
carcinogenicity is extremely expensive and time-consuming. Therefore, significant economic incentives
exist for developing alternatives to in vivo carcinogenicity testing.
Teratogenicity testing
Developmental abnormalities resulting from chemical agents are another important area of toxicological
concern. The story of thalidomide is a constant reminder of the toxicological problems associated with
fetal development, and is frequently used by both animal rights activists and the scientific community to

prove the value, or lack thereof, of animal testing. The activists indicate that not all species are affected
by thalidomide. Although this is true, it was the collective animal studies that provided the evidence that
thalidomide is a teratogen. In vitro and whole-animal metabolic studies later demonstrated the
mechanism of thalidomide-induced teratogenesis. In vitro approaches to this area of toxicity testing are
being actively pursued (16).
Target organ toxicity
Research efforts focus on cell cultures from specific organs to evaluate selective toxicity that occurs in
those particular organs. Extensive in vitro research is conducted on mechanisms of action. Progress has
been made in many areas, including hepatotoxicity (17), nephrotoxicity (18) and neurotoxicity (19, 20).
Toxicokinetic testing
Understanding the distribution and metabolism of toxicants is essential for toxicological risk assessment
(23). Many studies have investigated the relationship between in vitro and in vivo toxicokinetics. However,
because much remains to be accomplished, this area should receive priority in the future.
Structure-activity relationships
Current efforts attempt to correlate some general toxicological responses (lethality, ocular irritation,
cytotoxicity) with chemical parameters computed from the molecular structure of the test chemical (22,
23). At present, these methods are highly empirical, but are of value for regulatory purposes when other
data are not available. More mechanistic approaches are being developed (24). In the future, when
specific mechanistic effects can be related to chemical structure, these techniques may provide the
ultimate alternative method, since they depend only on computer analysis of the physicochemical
structure of molecules.
No single in vitro test will answer all toxicological questions. The many areas of toxicological concern
noted above involve very different biochemical-mechanistic processes; consequently, no one test is
currently adequate to evaluate this broad spectrum of endpoints. It will take ·batteries of in vitro tests to
obtain the information necessary to evaluate human risk resulting from exposure to potentially toxic
chemicals.
An important advantage of in vitro techniques in toxicity testing is that human cells can be used (27).
Advances in the biotechnology of human cell culture, in the cryopreservation of human tissue, and in
genetic engineering techniques to provide continuous supplies of normal, differentiated human cells are
helping to solve the problems of interspecies extrapolation of test data and to reduce the need for animals
in providing cells and tissues for toxicity testing systems.
Validation
Before any new test can be accepted, it must be validated. This process, which establishes the credibility
of a method for a particular purpose, consists of: a) establishment of test reliability; and b) development of
the scientific basis for interpretation of test results. A strategy for approaching validation involves a series
of logical steps (26, 27). First, the research scientist who actually developed the original test (called the
primary laboratory) must conduct an "intralaboratory assessment" and satisfy two requirements. One
requirement is standardising the test, meaning that the test protocol must be defined in a form that can be
transferred to other laboratories (referred to as secondary laboratories) with a reasonable likelihood of
success. The second requirement is that the primary laboratory must conduct a blind study to establish
the feasibility of the test as a useful alternative for some specific purpose and to provide quality-control

data for later comparisons. Once standardised in the primary laboratory, the test must be introduced into
the real world to see if it will work. This process, referred to as "interlaboratory assessment", is used to
evaluate whether secondary laboratories can obtain reproducible results. If secondary laboratories can
replicate results obtained in the primary laboratory, it is possible to start building a broad database ("test
database development") that can be used to determine how reliable test results are by evaluating the
false-positive rate, false-negative rate, sensitivity, specificity, and predictive value of the test: These data
are necessary before the test can be taken to the final level of development. The final stage of validation
is the time-consuming process of developing an understanding of the scientific basis of the test and
generating a large database for interpretation. The main problem in the implementation of in vitro testing
today is that the scientific community does not have the 50-60 years of experience that it has with in vivo
testing. It will take time to overcome the problems inherent in introducing new technologies and having
them accepted. Cumulative experience is what will ultimately boost in vitro approaches over the validation
hurdles.
Table 1: Tier testing strategy for incorporating in vitro toxicity testing into the risk assessment process
Tier

Title

Approach

1

Structure-activity analysis

Search literature for toxicity of structurally related chemicals based on
physicochemical properties.

2

In vitro testing as screens

Test for various aspects of toxicity using in vitro testing systems. Use
information provided to make initial regulatory decisions.

3

In vivo testing

Test chemicals in vivo only when additional toxicologic information is needed.
Note that little or no toxicity is expected at this stage because the more toxic
chemicals will have been identified at earlier stages.

Incorporation of In Vitro Methods in Risk Assessment
In vitro toxicity testing is a new, branch of toxicology and, as such, will require extensive research and
development to gain acceptance as a credible methodology for the toxicological evaluation of new
chemicals. In the short run, in vitro toxicity testing can be incorporated into the risk assessment process
through the use of tier testing strategies (Table 1). At an early level in a tier testing strategy, in vitro
methods can be used to select chemicals with the lowest probability for toxicity. Using this approach, only
chemicals expected to have little or no toxicity are ever tested in live animals. Such a strategy can be
utilised early in the development of new products to save the time and research and development costs
that would otherwise be lost, if invested in products that could not pass regulatory safety evaluations prior
to marketing. Finally, by looking further into the future, one can foresee a possible risk assessment
strategy that will be organised as illustrated in Figure 2. The risk of new chemicals will be evaluated on
the basis of in vitro data and structure-activity relationships rather than whole-animal testing.
Interest in the investigation of basic scientific questions that arise when innovative approaches are
applied to the problem of toxicity testing and safety evaluation has increased rapidly in the last 15 years.
Early questions in the area of carcinogenicity testing have been investigated in academic, government,
and industrial laboratories under the auspices of the National Toxicology Program (NTP) in the United
States, and the International Agency for Research on Cancer in France. For more than a decade, the
NTP has also supported fundamental research into alternatives in the area of teratogenicity. In the 1980s,
the Johns Hopkins CAAT has been involved in research, development, and validation activities in all
areas of toxicity testing, other than genotoxicity.

Figure 2: Future strategy for toxicity testing
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In vitro toxicity and toxicokinetic data will be utilised to provide the experimental database for risk asessment. In vitro
toxicokinetics data will be used in computer-generated, physiologically based toxicokinetic models, along with
traditional exposure estimates, to predict the concentrations of active forms of the chemical in the critical tissues. In
vitro dose-response relationships will be used to predict potential toxicologic risks associated with the expected level
of exposure. All these processes will be aided by structure-activity relationships based on mechanical responses.
Such a strategy would maximise the use of alternative toxicity testing methods in chemical safety evaluations.

Johns Hopkins Center for Alternatives to Animal Testing
The Johns Hopkins CAAT was founded in 1981 to address the major issues facing the development of
alternatives for toxicity testing. The goal of the Center is to develop and disseminate appropriate scientific
knowledge concerning innovative non-whole-animal methods for fully evaluating the safety of commercial
and therapeutic products. More specifically, CAAT: a) encourages basic research that will provide the
foundation for in vitro or other nonanimal test procedures for examining the toxicity of chemicals and/or
commercial products; b) develops specific methodologies that will provide alternative approaches to
whole-animal studies for the evaluation of safety; c) disseminates research progress through symposia,
publications and workshops; and d) encourages technology transfer and the use of in vitro methods in
regulatory consideration and product development.
To attain these goals, the Center has engaged in a variety of activities organised into three major
programmes: research; validation and technology; and education and communication.
Research
The Center's research programme consists of two components: the Research Grants Program and the In
Vitro Toxicology Laboratory. The Center has demonstrated that the investigator-initiated, peer-reviewed
grant process can produce major advances in a goal-oriented programme. This process has hastened the
development of alternatives and has helped to define the new discipline of in vitro toxicology. By the end
of fiscal year 1989, CAAT will have dispersed more than $2 million for more than 65 research projects.

Already, the research programme has produced more than 207 articles, book chapters, and symposium
presentations, including 85 papers written for peer-reviewed scientific journals.
To supplement its research programme, CAAT has established its own In Vitro Toxicology Laboratory.
The laboratory focuses on the development of new in vitro methods for chemical safety evaluation and is
involved in training researchers in vitro toxicology.
Validation and technology transfer
Validation and technology transfer activities of CAAT are conducted through a standing committee. The
objective of the Committee on Validation and Technology Transfer is to catalyse the transfer of new
testing technology from the research laboratory to practical application in toxicity assessment. This
committee is charged with developing a framework to assess existing programmes and coordinate future
activities, establishing a scientific structure for validation, and maintaining strong links with regulatory,
academic, and industrial activities. Long-range plans include developing a data bank to identify and
catalogue validation activities and in vitro methodologies in the United States developing an
administrative framework for validation, establishing the criteria for chemical selection for validation, and
forming a network of organisations for the exchange of information on validation activities.
Workshops are one mechanism the committees use to promote technology transfer. In 1989, CAAT held
the first in a series of technical workshops. The workshop addressed two problem areas: a) identification
of artifacts that adversely affect in vitro test results; and b) techniques to handle insoluble test chemicals
in in vitro test systems. Representatives from the regulatory and corporate communities participated in a
two-day workshop and collaborated in writing a technical report of the workshop. The proceedings of the
workshop were published by CAAT (28). Topics for future workshops include chemical selection for
validation; interpretation, extrapolation and relevance of in vitro data; good laboratory practices for in vitro
testing; and culture conditions and how they affect toxicity testing, validation, and information transfer.
Education and communication
Through its publications and presentations, CAAT has successfully drawn greater attention to new
approaches to toxicity testing and provided essential information to scientists, industry executives,
government officials, animal protection advocates, and the news media. The CAAT newsletter
(Alternative Methods in Toxicology) has grown from an initial circulation of 1000 to more than 20,000
reaching key international audiences.
Academic, industrial, and governmental scientists view the CAAT symposium as one of the major
international meetings on in vitro toxicology. These activities not only serve as a forum for cutting-edge
research, but also provide direction and cohesion to the new discipline. Alternative Methods in Toxicology
presents the proceedings of the annual symposia, as well as special topics of importance; Volume 7 was
published in the fall of 1989.
The CAAT Government Liaison Committee is a mechanism for exchanging information with interested
government representatives on animal issues, alternatives research, and regulatory acceptance of tests.
Through a regular exchange, CAAT hopes to heighten government interest in alternative research issues
and begin a long-term collaborative-education programme leading to regulatory acceptance of alternative
testing methodologies. The Committee for Public Information and Resources Development was
established to educate the public on the complex issues surrounding animal testing and alternatives.
Through a combination of these programmes, CAAT has been successful in promoting the development
of the new science of in vitro toxicity testing, as well as increasing awareness by the general public and

the scientific community of the scientific issues relating to toxicity testing. It is hoped that through the
application of current scientific knowledge and the development of new knowledge through coordinated
and focused research, non-whole-animal testing methods can be established as a significant component
of the chemical safety evaluation process.
Conclusion
The use of animals in biomedical activities – research, education, testing -- has come under increasing
scrutiny in recent years as a result of various factors, including economics, advances in biotechnology,
and animal welfare concerns. In many situations, new approaches allow for refinement, reduction, and, in
some cases, replacement of whole animals in activities that traditionally have depended on these model
systems. In the area of toxicity testing and safety evaluation, non-whole-animal techniques have made
significant contributions as screens and adjuncts. Whether alternative testing methods will completely
replace in vivo toxicity testing is a question that only time can answer. In the meantime alternative
methods can be employed to improve predictive toxicology and at the same time, significantly reduce
pain and distress in animals.
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